Ask a doctor about a prescription for CYSTAGON 50 mg HARD CAPSULES
Package Leaflet: Information for the User
CYSTAGON 50 mg Hard Capsules
CYSTAGON 150 mg Hard Capsules
cysteamine bitartrate (mercaptamine bitartrate)
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the package leaflet:
Cystinosis is a metabolic disease known as 'nephropathic cystinosis' characterized by the abnormal accumulation of the amino acid cystine in various organs of the body such as the kidneys, eyes, muscles, pancreas, and brain. The accumulation of cystine causes damage to the kidneys and the elimination of excessive amounts of sugar (glucose), proteins, and electrolytes. At different ages, different organs may be affected.
CYSTAGON is prescribed to treat this rare hereditary disorder. CYSTAGON is a medicine that reacts with cystine, reducing its levels in cells.
Do not take CYSTAGON:
Warnings and precautions:
Your doctor may periodically ask you for physical examinations of the skin and X-rays of the bones to monitor the effects of the medicine. Self-examination of the skin by the patient or parents is recommended. If any skin or bone abnormality appears, you should inform your doctor immediately.
Other medicines and CYSTAGON
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
CYSTAGON with food and drinks:
For children under six years of age, the hard capsule can be opened and its contents sprinkled on food (such as milk, potatoes, or starchy foods like flour), or mixed with the baby bottle. Do not mix with acidic drinks, such as orange juice. For complete instructions, consult your doctor.
Pregnancy
CYSTAGON should not be used during pregnancy. You should consult your doctor if you plan to become pregnant.
Breast-feeding
CYSTAGON should not be used during breast-feeding.
Driving and using machines:
CYSTAGON may cause drowsiness. When starting treatment, you or your child should avoid engaging in potentially hazardous activities until you are well aware of the effects of the medicine.
Follow your doctor's instructions for taking this medicine exactly. If you are in doubt, consult your doctor again.
The dose of CYSTAGON prescribed for you or your child will depend on their weight and age.
For children up to 12 years of age, the dose will be based on body size (surface area), with the usual dose being 1.30 g/m2 of body surface area per day.
For patients over 12 years of age and weighing more than 50 kg, the usual dose is 2 g/day.
In any case, the usual dose should not exceed 1.95 g/m2/day.
CYSTAGON should always be taken orally and exactly as instructed by your doctor or your child's doctor. To ensure CYSTAGON works properly, it is necessary:
CYSTAGON should be taken 4 times a day, every 6 hours, preferably with meals or immediately after meals. It is essential to respect the rule of taking the dose every six hours as strictly as possible.
Treatment with CYSTAGON should be continued indefinitely as indicated by your doctor.
To easily open and close the CYSTAGON bottle, follow the instructions below:
Instructions for opening and closing the container
OPEN | CLOSE |
To open the container Place a pen or a similar object between the raised parts of the cap and turn it in the indicated direction (counterclockwise) | To close the container Place a pen or a similar object between the raised parts of the cap and turn it in the indicated direction (clockwise) |
If you take more CYSTAGON than you should
If you have taken more medicine than prescribed, or if drowsiness occurs, consult your doctor or your child's doctor immediately, or go to the emergency department of a hospital.
If you forget to take CYSTAGON
If you have forgotten to take a dose of the medicine, take it as soon as possible. However, if it is less than 2 hours until the next dose, you should skip the missed dose and return to the normal schedule. Do not take a double dose to make up for forgotten doses.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
CYSTAGON may cause drowsiness or decreased alertness in some people. Make sure you know how you or your child reacts to this medicine before engaging in any activity that may be hazardous if you are not alert.
The following side effects have been reported:
Since some of these side effects are serious, ask your doctor or pediatrician to explain the warning signs.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of the month shown.
Do not store above 25°C.
Keep the container tightly closed to protect it from light and moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of CYSTAGON
Appearance of the product and pack contents
Hard capsules
Bottles of 100 or 500 hard capsules. Some pack sizes may not be marketed.
Bottles of 100 or 500 hard capsules. Some pack sizes may not be marketed.
Marketing authorisation holder
Recordati Rare Diseases
Immeuble “Le Wilson”
70, Avenue du Général de Gaulle
F-92800 Puteaux
France
Manufacturer
Recordati Rare Diseases
Immeuble “Le Wilson”
70, Avenue du Général de Gaulle
F-92800 Puteaux
France
or
Recordati Rare Diseases
Eco River Parc
30, rue des Peupliers
F-92000 Nanterre
France
You can obtain further information on this medicine by contacting the local representative of the marketing authorisation holder.
België/Belgique/Belgien Recordati Tél/Tel: +32 2 46101 36 | Lietuva Recordati AB. Tel: + 46 8 545 80 230 Švedija |
Luxembourg/Luxemburg Recordati Tél/Tel: +32 2 46101 36 Belgique/Belgien | |
Ceská republika Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Francie | Magyarország Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Franciaország |
Danmark Recordati AB. Tlf : +46 8 545 80 230 Sverige | Malta Recordati Rare Diseases Tel: +33 1 47 73 64 58 Franza |
Deutschland Recordati Rare Diseases Germany GmbH Tel: +49 731 140 554 0 | Nederland Recordati Tel: +32 2 46101 36 België |
Eesti Recordati AB. Tel: + 46 8 545 80 230 Rootsi | Norge Recordati AB. Tlf : +46 8 545 80 230 Sverige |
Ελλ?δα Recordati Rare Diseases Τηλ: +33 1 47 73 64 58 Γαλλ?α | Österreich Recordati Rare Diseases Germany GmbH Tel: +49 731 140 554 0 Deutschland |
España Recordati Rare Diseases Spain S.L.U. Tel: + 34 91 659 28 90 | Polska Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Francja |
France Recordati Rare Diseases Tél: +33 (0)1 47 73 64 58 | Portugal Jaba Recordati S.A. Tel: +351 21 432 95 00 |
Hrvatska Recordati Rare Diseases Tél: +33 (0)1 47 73 64 58 Francuska | România Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Franta |
Ireland Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France | Slovenija Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Francija |
Ísland Recordati AB. Simi:+46 8 545 80 230 Svíþjóð | Slovenská republika Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Francúzsko |
Italia Recordati Rare Diseases Italy Srl Tel: +39 02 487 87 173 | Suomi/Finland Recordati AB. Puh/Tel : +46 8 545 80 230 Sverige |
Κ?προς Recordati Rare Diseases Τηλ : +33 1 47 73 64 58 Γαλλ?α | Sverige Recordati AB. Tel : +46 8 545 80 230 |
Latvija Recordati AB. Tel: + 46 8 545 80 230 Zviedrija | United Kingdom (Northern Ireland) Recordati Rare Diseases UK Ltd. Tel: +44 (0)1491 414333 |
Date of last revision of this leaflet:07/2024
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CYSTAGON 50 mg HARD CAPSULES – subject to medical assessment and local rules.